Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Barrick Gold Corporation (NYSE: ABX) shares closed up 3.72 percent on Tuesday with about 9.3 million shares traded. The stock was one of the most active stocks traded. The company announced its plans to divest the Plutonic mine in Western Australia to Northern Star Resources Ltd for total cash consideration of A$25 million. The transaction is subject to certain closing conditions and is expected to close in Feb 2014.
Get more information on Barrick Gold Corporation and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/ABX
Enzon Pharmaceuticals Inc. (NASDAQ: ENZN) shares closed down 28.13 percent on Tuesday with about 3.7 million shares traded. The stock was one of the biggest decliners on the NASDAQ and hit a new 52-week low of $1.13 during intra-day trading. The company had no significant news released.
Get more information on Enzon Pharmaceuticals Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/ENZN
Dewmar International BMC, Inc. (OTC: DEWM) shares closed up 85.71 percent on Tuesday with nearly 250 million shares traded. The stock was one of the biggest gainers in the OTC market. The company has had no significant news since providing shareholders with an update on December 11th. Dewmar International BMC, Inc., through its subsidiary DSD Network of America, Inc., engages in the manufacture and sale of Lean Slow Motion Potion brand relaxation beverage primarily in the United States, Trinidad and Tobago, and Mexico.
Get more information on Dewmar International BMC, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/DEWM
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) shares closed up 28.10 percent on Tuesday with about 1.6 million shares traded. The stock was one of the biggest gainers in the NASDAQ and hit a new 52-week high of $16.38 during intra-day trading. The company, a developer of oral drug delivery systems, announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per share in a registered direct offering. The offering is expected to close on or about December 31, 2013, subject to the satisfaction of customary closing conditions.
Get more information on Oramed Pharmaceuticals Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/ORMP
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.